Key Insights

Highlights

Success Rate

86% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

13.0%

3 terminated out of 23 trials

Success Rate

86.4%

-0.1% vs benchmark

Late-Stage Pipeline

30%

7 trials in Phase 3/4

Results Transparency

11%

2 of 19 completed with results

Key Signals

2 with results86% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (2)
P 1 (1)
P 2 (12)
P 3 (7)

Trial Status

Completed19
Terminated3
Unknown1

Trial Success Rate

86.4%

Benchmark: 86.5%

Based on 19 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT01085617Completed

Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

NCT05039593Not ApplicableCompletedPrimary

Oral Care Frequency in Mechanically Ventilated Patients

NCT02015559Phase 2Completed

Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus

NCT00004234Phase 3Completed

Oral Mucositis in Patients Receiving Radiation Therapy for Cancer of the Mouth, Pharynx, or Larynx

NCT00003686Phase 3TerminatedPrimary

Pilocarpine in Treating Patients With Dry Mouth Caused by Opioids

NCT02123511Phase 2Completed

Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy

NCT02273752Phase 2Terminated

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

NCT00002533Phase 2Completed

Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00036881Phase 3Completed

Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00080873Not ApplicableCompleted

Traumeel® S in Preventing and Treating Mucositis in Young Patients Undergoing Stem Cell Transplantation

NCT00003139Phase 3Completed

Pilocarpine in Preventing Mucositis and Dry Mouth in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00003313Phase 3Completed

Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer

NCT00008398Phase 3Completed

Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer

NCT00004256Phase 2Completed

Sargramostim to Prevent Mucositis in Patients Receiving Radiation Therapy for Laryngeal Cancer

NCT00036712Phase 2Unknown

Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation

NCT00004061Phase 2Completed

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

NCT00003580Phase 2Completed

Amifostine to Treat Side Effects of Treatment in Patients Receiving Radiation Therapy and Cisplatin for Advanced Head and Neck Cancer

NCT00004132Phase 2Completed

Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

NCT00003193Phase 1Completed

Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer

NCT00025298Phase 2Terminated

Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx

Scroll to load more

Research Network

Activity Timeline